



IRV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/705,757 Confirmation No. : 4848
First Named : Eberhard WEIHE
Applicant
Filed : November 12, 2003
TC/A.U. : 1743
Examiner : Unassigned
Docket No. : 029310.52818US
Customer No. : 23911
Title : Screening Method Using Pim1-Kinase or Pim3-Kinase

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R § § 1.97 AND 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.


STATEMENT OF RELEVANCE

The relevance of these references to the subject matter of the present invention is given in the specification of the present invention.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



J. D. Evans
Registration No. 26,269
Song Zhu, Ph.D.
Registration No. 44,420

November 2, 2004

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/705,757		
		Filing Date	November 12, 2003		
		First Named Inventor	Eberhard WEIHE		
		Art Unit	1743		
		Examiner Name	Unassigned		
Sheet	1	of	4	Attorney Docket Number	029310.52818US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	AA	US-	5,262,311	11-16-1993	Arthur B. Pardee et al.	
		US-				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AB	ARMEN N. AKOPIAN ET AL., "A Tetrodotoxin-Resistant Voltage-Gated Sodium Channel Expressed by Sensory Neurons", Letters to Nature, January 18, 1996, pp. 257-262, Vol. 379	
	AC	JAMES A. BONINI ET AL., "Molecular Cloning and Tissue Expression of a Novel Orphan G Protein-Coupled Receptor from Rat Lung", Biochemical and Biophysical Research Communications, 1997, pp. 190-193, 234, Article no. RC976591, Academic Press	
	AD	ANTHONY DICKENSON ET AL., "Novel Pharmacological Targets in the Treatment of Pain", Pain Reviews, 1995, pp. 1-12, 2, Edward Arnold	
	AE	TATSUO FURUKAWA ET AL., "Identification of New Genes Expressed in a Human Erythroleukemia Cell Line", Blood Cells, Molecules and Diseases, 1996, pp. 11-22, 22, 2, The Blood Cells Foundation, LaJolla, California, USA	
	AF	M. HUBANK ET AL., "Identifying Differences in mRNA Expression by Representational Difference Analysis of cDNA", Nucleic Acids Research, 1994, pp. 5640-5648, Vol. 22, No. 25	
	AG	PENG LIANG ET AL., "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction", Science, August 14, 1992, pp. 967-971, Vol. 257	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/705,757
				Filing Date	November 12, 2003
				First Named Inventor	Eberhard WEIHE
				Art Unit	1743
Examiner Name	Unassigned				
Sheet	2	of	4	Attorney Docket Number	029310.52818US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AH	G.M.-C. POIRIER ET AL., "Screening Differentially Expressed cDNA Clones Obtained by Differential Display Using Amplified RNA", Nucleic Acids Research, 1997, pp. 913-914, Vol. 25, No. 4, Oxford University Press	
	AI	THOMAS R. TÖLLE, "Chronischer Schmerz", 1997	
	AJ	JACKSON S. WAN ET AL., "Cloning Differentially Expressed mRNAs", Nature Biotechnology, December 1996, pp. 1685-1691, Volume 14	
	AK	CLIFFORD J. WOOLF ET AL., "Peripheral Nerve Injury Triggers Central Sprouting of Myelinated Afferents", Letters to Nature, January 2, 1992, pp. 75-78, Vol. 355	
	AL	HIROSHI BABA ET AL., "Peripheral Inflammation Facilitates A β Fiber-Mediated Synaptic Input to the Substantia Gelatinosa of the Adult Rat Spinal Cord", The Journal of Neuroscience, January 15, 1999, pp. 859-867, 19, 2, Society for Neuroscience	
	AM	CHIH-CHENG CHEN ET AL., "A P2X Purinoceptor Expressed by a Subset of Sensory Neurons", Letters to Nature, October 5, 1995, pp. 428-431, Vol. 377	
	AN	DAVID DUBUISSON ET AL., "The Formalin Test: A Quantitative Study of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats", Pain, 1977, pp. 161-174, 4, Elsevier/North-Holland Biomedical Press	
	AO	P.G. GUNASEKAR ET AL., "NMDA Receptor Activation Produces Concurrent Generation of Nitric Oxide and Reactive Oxygen Species: Implication for Cell Death", Journal of Neurochemistry, 1995, p. 2016-2021, Vol. 65, No. 5, Lippincott-Raven Publishers, Philadelphia, USA	
	AP	SVEN KLUßMANN ET AL., "Mirror-Image RNA that Binds D-Adenosine", Nature Biotechnology, September 1996, pp. 1112-1115, Vol. 14	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/705,757
		Filing Date	November 12, 2003
		First Named Inventor	Eberhard WEIHE
		Art Unit	1743
		Examiner Name	Unassigned
Sheet 3 of 4	Attorney Docket Number	029310.52818US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AQ	AXEL METHNER ET AL., "A Novel G Protein-Coupled Receptor with Homology to Neuropeptide and Chemoattractant Receptors Expressed during Bone Development", 1997, pp. 336-342, 233, Article no. RC976455, Academic Press	
	AR	LAUREN SOMPAYRAC ET AL., "Overcoming Limitations of the mRNA Differential Display Technique", Nucleic Acids Research, 1995, pp. 4738-4739, Vol. 23, No. 22, Oxford University Press	
	AS	JOSEPH B. WATSON ET AL., "Differential cDNA Screening Strategies to Identify Novel Stage-Specific Proteins in the Developing Mammalian Brain", Dev. Neurosci., 1993, pp. 77-86, 15	
	AT	M. ZIMMERMANN ET AL., "Plasticity of the Nervous System at the Systemic, Cellular and Molecular Levels: a Mechanism of Chronic Pain and Hyperalgesia", Progress in Brain Research, 1996, pp. 233-259, Vol. 110, Elsevier Science B.V.	
	AU	DAVID BAUER ET AL., "Identification of Differentially Expressed mRNA Species by an Improved Display Techniques (DDRT-PCR)", Nucleic Acids Research, 1993, pp. 4272-4280, Vol. 21, No. 18, Oxford University Press	
	AV	TERENCE J. CODERRE ET AL., "Contribution of Central Neuroplasticity to Pathological Pain: Review of Clinical and Experimental Evidence", Pain, 1993, pp. 259-285, 52, Elsevier Science Publishers B.V.	
	AW	YUN FENG ET AL., "Cloning of a Novel Member of the G Protein-Coupled Receptor Family Related to Peptide Receptors", Biochemical and Biophysical Research Communications, 1997, pp. 651-654, 231, Article No. RC976161, Academic Press	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/705,757
		Filing Date	November 12, 2003
		First Named Inventor	Eberhard WEIHE
		Art Unit	1743
		Examiner Name	Unassigned
Sheet 4 of 4	Attorney Docket Number	029310.52818US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AX	BRIAN E. HAWES ET AL., "Nociceptin (ORL-1) and μ -Opioid Receptors Mediate Mitrogen-Activated Protein Kinase in CHO Cells Through a G _i -Coupled Signaling Pathway: Evidence for Distinct Mechanisms of Agonist-Mediated Desensitization", Journal of Neurochemistry, 1998, pp. 1024-1033, Vol. 71, No. 3, International Society of Neurochemistry	
	AY	LING-YUAN LI ET AL., "The Stimulatory Effect of Opioids on Mitrogen-Activated Protein Kinase in Chinese Hamster Ovary Cells Transfected to Express μ -Opioid Receptors", Molecular Pharmacology, 1996, pp. 599-602, 50, The American Society for Pharmacology and Experimental Therapeutics	
	AZ	ABDI A. MOHIT ET AL., "p49 ^{3F12} Kinase: A Novel MAP Kinase Expressed in a Subset of Neurons in the Human Nervous System", Neuron, January 1995, pp. 67-78, Vol. 14, Cell Press	
	BA	VICTOR E. VELCULESCU ET AL., "Serial Analysis of Gene Expression", Science, October 20, 1995, pp. 484-487, Vol. 270	
	BB	ANDREW F. WILKS, "Two Putative Protein-Tyrosine Kinases Identified by Application of the Polymerase Chain Reaction", Genetics, March 1989, pp. 1603-1607, Vol. 86, Proc. Natl. Acad. Sci., USA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2